SEC Form D filing

Quince Therapeutics, Inc., 2026-06-11

An SEC Form D private-offering notice from South San Francisco, CA, a $186,422,679 filer-stated offering target in Biotech. Filed 2026-06-11. The source filing is one click away. For companies that filed this week, open the live feed.

What this filing says

Quince Therapeutics, Inc. site↗ Verified via SEC Form D

Late stage biotechnology company developing EryDex, an autologous red blood cell encapsulated drug therapy for the rare neurodegenerative disease ataxia telangiectasia.

Filed 2026-06-11Filed to raise $186,422,679First money in 2026-05-18Raised so far $114,720,542HQ (as filed) South San Francisco, CASector Biotech web-verified against the company’s own siteStage (inferred) LateCall status Delayed filing
Source linked the Form D on EDGAR↗Website verified quincetx.com↗Named in the filing 7 executives & directors

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.

Other Form D filings from the same week

each with its own page and its own EDGAR source